Young Bin Joo1, Yune-Jung Park1, Kyung-Su Park1, Ki-Jo Kim2. 1. Division of Rheumatology, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, 93 Jungbu-daero, Paldal-gu, Suwon, Gyeonggi-do, 16247, Republic of Korea. 2. Division of Rheumatology, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, 93 Jungbu-daero, Paldal-gu, Suwon, Gyeonggi-do, 16247, Republic of Korea. md21c@catholic.ac.kr.
Abstract
INTRODUCTION: Antibody against cyclic citrullinated protein (ACPA) is counted as one of the most important biomarkers in diagnosis, classification, and prognosis of rheumatoid arthritis (RA). We examined the evolution of ACPA during disease course and assess predictive value of time-weighted cumulative ACPA titer on radiographic progression in RA patients. METHOD: A group of 734 patients with RA was followed longitudinally over 2 years, with annual measurements of ACPA. The cumulative titers of ACPA were calculated using the trapezoidal rule and were divided into three categories: negative, low-to-moderate, and high. Radiographs of the hands were scored with the modified Sharp score (SHS). Multivariable logistic regression models were performed to identify independent predictors over follow-up for individual patients with different combinations of risk factors. The effect size was computed by Cohen's d method. RESULTS: The patients with radiographic progression had a higher SHS at baseline; and smoking status, diabetes, RF positivity, and use of biologic DMARDs were independently associated with radiographic progression (all P < 0.05). As for ACPA, reversion happened more commonly in men and was associated with younger onset age and lower titer at baseline, but it had no direct relevance to radiographic outcome. In multivariable regression analysis, only high cumulative or baseline titer of ACPA had a predictive power for rapid radiographic progression (all P < 0.05), and cumulative ACPA titer was superior in terms of statistical significance (Cohen's d, 0.637 versus 0.583). CONCLUSIONS: High cumulative ACPA titer was independently associated with accelerated radiographic progression, especially with initiation of joint damage.
INTRODUCTION: Antibody against cyclic citrullinated protein (ACPA) is counted as one of the most important biomarkers in diagnosis, classification, and prognosis of rheumatoid arthritis (RA). We examined the evolution of ACPA during disease course and assess predictive value of time-weighted cumulative ACPA titer on radiographic progression in RApatients. METHOD: A group of 734 patients with RA was followed longitudinally over 2 years, with annual measurements of ACPA. The cumulative titers of ACPA were calculated using the trapezoidal rule and were divided into three categories: negative, low-to-moderate, and high. Radiographs of the hands were scored with the modified Sharp score (SHS). Multivariable logistic regression models were performed to identify independent predictors over follow-up for individual patients with different combinations of risk factors. The effect size was computed by Cohen's d method. RESULTS: The patients with radiographic progression had a higher SHS at baseline; and smoking status, diabetes, RF positivity, and use of biologic DMARDs were independently associated with radiographic progression (all P < 0.05). As for ACPA, reversion happened more commonly in men and was associated with younger onset age and lower titer at baseline, but it had no direct relevance to radiographic outcome. In multivariable regression analysis, only high cumulative or baseline titer of ACPA had a predictive power for rapid radiographic progression (all P < 0.05), and cumulative ACPA titer was superior in terms of statistical significance (Cohen's d, 0.637 versus 0.583). CONCLUSIONS: High cumulative ACPA titer was independently associated with accelerated radiographic progression, especially with initiation of joint damage.
Authors: J Rönnelid; M C Wick; J Lampa; S Lindblad; B Nordmark; L Klareskog; R F van Vollenhoven Journal: Ann Rheum Dis Date: 2005-04-20 Impact factor: 19.103
Authors: E J Kroot; B A de Jong; M A van Leeuwen; H Swinkels; F H van den Hoogen; M van't Hof; L B van de Putte; M H van Rijswijk; W J van Venrooij; P L van Riel Journal: Arthritis Rheum Date: 2000-08
Authors: Paco M J Welsing; Robert B M Landewé; Piet L C M van Riel; Maarten Boers; Anke M van Gestel; Sjef van der Linden; Hilde L Swinkels; Désirée M F M van der Heijde Journal: Arthritis Rheum Date: 2004-07
Authors: Markus M J Nielen; Dirkjan van Schaardenburg; Henk W Reesink; Rob J van de Stadt; Irene E van der Horst-Bruinsma; Margret H M T de Koning; Moud R Habibuw; Jan P Vandenbroucke; Ben A C Dijkmans Journal: Arthritis Rheum Date: 2004-02
Authors: Geraldine Cambridge; Maria J Leandro; Jonathan C W Edwards; Michael R Ehrenstein; Martin Salden; Mark Bodman-Smith; Anthony D B Webster Journal: Arthritis Rheum Date: 2003-08
Authors: Bernardo D'Onofrio; Michele di Lernia; Ludovico De Stefano; Serena Bugatti; Carlomaurizio Montecucco; Laura Bogliolo Journal: J Clin Med Date: 2022-04-22 Impact factor: 4.964